Top

Published in:

01-08-2020 | Kidney Transplantation | Review

Therapeutic management of HIV-infected patients with chronic kidney disease

Authors: Gaetano Alfano, Giovanni Guaraldi, Francesco Fontana, Antonio Bellasi, Gianni Cappelli

Published in: Journal of Nephrology | Issue 4/2020

Abstract

CKD and HIV infection are two chronic diseases impacting heavily on the survival of the affected patients. The interplay between HIV infection and chronic kidney disease (CKD) is complex and interactions occur at multiple levels. Approach to the management of HIV-infected patients requires special attention to face the numerous therapeutic difficulties ranging from drug-drug interactions to drug-toxicity. The most effective strategy is targeted to suppression of HIV viral load, as it dramatically changes the prognosis of the patients as well as prevents the development of HIV-associated kidney disease. As shown in this review, the approach to the therapeutic management of CKD in the setting of HIV infection varies in relation to the degree of renal impairment.

UNAIDS Science Panel (2018) Making the end of AIDS real: consensus building around what we mean by “epidemic control.” Geneva: UNAIDS. https://www.unaids.org/sites/default/files/media_asset/glion_oct2017_meeting_report_en.pdf, Accessed 4 July 2019. https://www.unaids.org/sites/default/files/media_asset/2019-UNAIDS-data_en.pdf. Accessed 15 Sept 2019

Wu P-Y, Hung C-C, Liu W-C et al (2012) Metabolic syndrome among HIV-infected Taiwanese patients in the era of highly active antiretroviral therapy: prevalence and associated factors. J Antimicrob Chemother 67(4):1001–1009. https://doi.org/10.1093/jac/dkr558 CrossRefPubMed

Ekrikpo UE, Kengne AP, Bello AK et al (2018) Chronic kidney disease in the global adult HIV-infected population: a systematic review and meta-analysis. PLoS ONE 13(4):e0195443. https://doi.org/10.1371/journal.pone.0195443 CrossRefPubMedPubMedCentral

Lucas GM, Mehta SH, Atta MG et al (2007) End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS Lond Engl 21(18):2435–2443. https://doi.org/10.1097/QAD.0b013e32827038ad CrossRef

Bansi L, Hughes A, Bhagani S et al (2009) Clinical epidemiology of HIV-associated end-stage renal failure in the UK. AIDS Lond Engl 23(18):2517–2521. https://doi.org/10.1097/QAD.0b013e3283320e12 CrossRef

Freiberg MS, Chang C-CH, Kuller LH et al (2013) HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 173(8):614–622. https://doi.org/10.1001/jamainternmed.2013.3728 CrossRefPubMedPubMedCentral

Pereyra F, Lo J, Triant VA et al (2012) Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS Lond Engl 26(18):2409–2412. https://doi.org/10.1097/QAD.0b013e32835a9950 CrossRef

Deeks SG, Tracy R, Douek DC (2013) Systemic effects of inflammation on health during chronic HIV infection. Immunity 39(4):633–645. https://doi.org/10.1016/j.immuni.2013.10.001 CrossRefPubMedPubMedCentral

Ibáñez L, Velli PS, Font R et al (2014) HIV-infection, atherosclerosis and the inflammatory pathway: candidate gene study in a spanish HIV-infected population. PLoS ONE. https://doi.org/10.1371/journal.pone.0112279 CrossRefPubMedPubMedCentral

10.

Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf. AIDSinfo. https://aidsinfo.nih.gov/guidelines. Accessed 1 July 2019

11.

EACS, Guidelines version 9.1, October 2018.

12.

Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018 (WHO/CDS/HIV/18.51). Licence: CC BY-NC-SA 3.0 IGO

13.

Alfano G, Cappelli G, Fontana F et al (2019) Kidney disease in HIV infection. J Clin Med 8(8):1254. https://doi.org/10.3390/jcm8081254 CrossRefPubMedCentral

14.

Gara N, Zhao X, Collins MT et al (2012) Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther 35(11):1317–1325. https://doi.org/10.1111/j.1365-2036.2012.05093.x CrossRefPubMedPubMedCentral

15.

Iwata K, Nagata M, Watanabe S, Nishi S (2016) Distal renal tubular acidosis without renal impairment after use of tenofovir: a case report. BMC Pharmacol Toxicol. https://doi.org/10.1186/s40360-016-0100-y CrossRefPubMedPubMedCentral

16.

Casado JL, Bañón S, Santiuste C et al (2016) Prevalence and significance of proximal renal tubular abnormalities in HIV-infected patients receiving tenofovir. AIDS Lond Engl 30(2):231–239. https://doi.org/10.1097/QAD.0000000000000901 CrossRef

17.

Lucas GM, Ross MJ, Stock PG et al (2014) Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis 59(9):e96–e138. https://doi.org/10.1093/cid/ciu617 CrossRefPubMedPubMedCentral

18.

Custodio JM, Fordyce M, Garner W et al (2016) Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment. Antimicrob Agents Chemother 60(9):5135–5140. https://doi.org/10.1128/AAC.00005-16 CrossRefPubMedPubMedCentral

19.

Post FA, Tebas P, Clarke A et al (2017) Brief report: switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected adults with renal impairment: 96-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 1999 74(2):180–184. https://doi.org/10.1097/QAI.0000000000001186 CrossRef

20.

Mills A, Arribas JR, Andrade-Villanueva J et al (2016) Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 16(1):43–52. https://doi.org/10.1016/S1473-3099(15)00348-5 CrossRefPubMed

21.

Bunnell KL, Vibhakar S, Glowacki RC, Gallagher MA, Osei AM, Huhn G (2016) Nephrotoxicity associated with concomitant use of ledipasvir-sofosbuvir and tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection. Pharmacotherapy 36(9):e148–153. https://doi.org/10.1002/phar.1803 CrossRefPubMed

22.

Novick TK, Choi MJ, Rosenberg AZ, McMahon BA, Fine D, Atta MG (2017) Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: a case report. Medicine (Baltimore). 96(36):e8046. https://doi.org/10.1097/MD.0000000000008046 CrossRefPubMedPubMedCentral

23.

Bahr NC, Yarlagadda SG (2019) Fanconi Syndrome and tenofovir alafenamide: a case report. Ann Intern Med 170(11):814. https://doi.org/10.7326/L18-0592 CrossRefPubMed

24.

Tattevin P, Revest M, Chapplain J-M, Ratajczak-Enselme M, Arvieux C, Michelet C (2013) Increased risk of renal stones in patients treated with atazanavir. Clin Infect Dis Off Publ Infect Dis Soc Am 56(8):1186. https://doi.org/10.1093/cid/cis1211 CrossRef

25.

Izzedine H, Lescure FX, Bonnet F (2014) HIV medication-based urolithiasis. Clin Kidney J 7(2):121–126. https://doi.org/10.1093/ckj/sfu008 CrossRefPubMedPubMedCentral

26.

de Lastours V, Ferrari Rafael De Silva E, Daudon M et al (2013) High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients. J Antimicrob Chemother 68(8):1850–1856. https://doi.org/10.1093/jac/dkt125 CrossRefPubMed

27.

Friis-Møller N, Weber R, Reiss P et al (2003) Cardiovascular disease risk factors in HIV patients—association with antiretroviral therapy. Results from the DAD study. AIDS Lond Engl 17(8):1179–1193. https://doi.org/10.1097/01.aids.0000060358.78202.c1 CrossRef

28.

Dorjee K, Choden T, Baxi SM, Steinmaus C, Reingold AL (2018) Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents 52(5):541–553. https://doi.org/10.1016/j.ijantimicag.2018.07.010 CrossRefPubMed

29.

Palacios R, Mayorga M, González-Domenech CM et al (2018) Safety and efficacy of dolutegravir plus rilpivirine in treatment-experienced HIV-infected patients: the DORIVIR study. J Int Assoc Provid AIDS Care JIAPAC. https://doi.org/10.1177/2325958218760847 CrossRefPubMed

30.

Jabłonowska E, Siwak E, Bociąga-Jasik M et al (2019) Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PLoS ONE 14(1):e0210476. https://doi.org/10.1371/journal.pone.0210476 CrossRefPubMedPubMedCentral

31.

Taiwo BO, Marconi VC, Berzins B et al (2018) Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial. Clin Infect Dis Off Publ Infect Dis Soc Am 66(11):1794–1797. https://doi.org/10.1093/cid/cix1131 CrossRef

32.

Levey AS, Stevens LA (2010) Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis Off J Natl Kidney Found 55(4):622–627. https://doi.org/10.1053/j.ajkd.2010.02.337 CrossRef

33.

Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis Off J Natl Kidney Found 40(2):221–226. https://doi.org/10.1053/ajkd.2002.34487 CrossRef

34.

Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 3:1–150. 93. https://www.kidney-international.org/article/S0085-2538(18)30118-2/abstract. Accessed 18 Nov 2018

35.

Ki-Chul S, Seungho R, Jong-Young L et al (2016) Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. J Am Heart Assoc 5(9):e003245. https://doi.org/10.1161/JAHA.116.003245 CrossRef

36.

Inker LA, Astor BC, Fox CH et al (2014) KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis Off J Natl Kidney Found 63(5):713–735. https://doi.org/10.1053/j.ajkd.2014.01.416 CrossRef

37.

Swanepoel CR, Atta MG, D’Agati VD et al (2018) Kidney disease in the setting of HIV infection: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 93(3):545–559. https://doi.org/10.1016/j.kint.2017.11.007 CrossRefPubMedPubMedCentral

38.

EACS Guidelines as follows: EACS Guidelines version 10.0 (2019) https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed 22 Dec 2019

39.

Delanaye P, Jager KJ, Bökenkamp A et al (2019) CKD: a call for an age-adapted definition. J Am Soc Nephrol JASN 30(10):1785–1805. https://doi.org/10.1681/ASN.2019030238 CrossRefPubMed

40.

Whelton PK, Carey RM, Aronow WS et al (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertens Dallas Tex 1979 71(6):1269–1324. https://doi.org/10.1161/HYP.0000000000000066 CrossRef

41.

Rosenson RS, Colantonio LD, Burkholder GA, Chen L, Muntner P (2018) Trends in utilization of statin therapy and contraindicated statin use in HIV–infected adults treated with antiretroviral therapy from 2007 through 2015. J Am Heart Assoc 7(24):e010345. https://doi.org/10.1161/JAHA.118.010345 CrossRefPubMedPubMedCentral

42.

Research C for DE and FDA Drug Safety Communication: Serious liver disorder associated with the use of Videx/Videx EC (didanosine). FDA (2019) https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-serious-liver-disorder-associated-use-videxvidex-ec-didanosine. Accessed 25 July 2019

43.

Fichtenbaum CJ, Gerber JG (2002) Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 41(14):1195–1211. https://doi.org/10.2165/00003088-200241140-00004 CrossRefPubMed

44.

Song IH, Zong J, Borland J et al (2016) The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr 1999 72(4):400–407. https://doi.org/10.1097/QAI.0000000000000983 CrossRef

45.

Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56(3):305–314. https://doi.org/10.1046/j.0306-5251.2003.01862.x CrossRefPubMedPubMedCentral

46.

May M, Schindler C (2016) Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab 7(2):69–83. https://doi.org/10.1177/2042018816638050 CrossRefPubMedPubMedCentral

47.

Trullas JC, Mocroft A, Cofan F et al (2010) Dialysis and renal transplantation in HIV-infected patients: a European survey. J Acquir Immune Defic Syndr 1999 55(5):582–589. https://doi.org/10.1097/QAI.0b013e3181efbe59 CrossRef

48.

Rastegar DA, Knight AM, Monolakis JS (2006) Antiretroviral medication errors among hospitalized patients with HIV infection. Clin Infect Dis Off Publ Infect Dis Soc Am 43(7):933–938. https://doi.org/10.1086/507538 CrossRef

49.

Tourret J, Tostivint I, Du Montcel ST et al (2007) Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis. Clin Infect Dis Off Publ Infect Dis Soc Am 45(6):779–784. https://doi.org/10.1086/521168 CrossRef

50.

Achenbach CJ, Darin KM, Murphy RL, Katlama C (2011) Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults. Future Virol 6(2):157–177. https://doi.org/10.2217/fvl.10.89 CrossRefPubMedPubMedCentral

51.

Eron JJ, Lelievre J-D, Kalayjian R et al (2018) Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial. Lancet HIV. https://doi.org/10.1016/S2352-3018(18)30296-0 CrossRefPubMed

52.

Michienzi SM, Schriever CA, Badowski ME (2019) Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis. Int J STD AIDS 30(2):181–187. https://doi.org/10.1177/0956462418800865 CrossRefPubMed

53.

Schloth T, Genabe I, Pilgrim W, Jorden A, Fein PA, Avram MM (1992) Peritonitis and the patient with human immunodeficiency virus (HIV). Adv Perit Dial Conf Perit Dial 8:250–252

54.

Dressler R, Peters AT, Lynn RI (1989) Pseudomonal and candidal peritonitis as a complication of continuous ambulatory peritoneal dialysis in human immunodeficiency virus-infected patients. Am J Med 86(6 Pt 2):787–790. https://doi.org/10.1016/0002-9343(89)90474-9 CrossRefPubMed

55.

Punyawudho B, Singkham N, Thammajaruk N et al (2016) Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients. Expert Rev Clin Pharmacol 9(12):1583–1595. https://doi.org/10.1080/17512433.2016.1235972 CrossRefPubMed

56.

Ndlovu KCZ, Assounga A (2017) Continuous ambulatory peritoneal dialysis in patients with hiv and end-stage renal failure. Perit Dial Int J Int Soc Perit Dial 37(3):321–330. https://doi.org/10.3747/pdi.2016.00165 CrossRef

57.

Locke JE, Gustafson S, Mehta S et al (2017) Survival benefit of kidney transplantation in HIV-infected patients. Ann Surg 265(3):604–608. https://doi.org/10.1097/SLA.0000000000001761 CrossRefPubMedPubMedCentral

58.

Locke JE, Mehta S, Reed RD et al (2015) A national study of outcomes among HIV-infected kidney transplant recipients. J Am Soc Nephrol JASN 26(9):2222–2229. https://doi.org/10.1681/ASN.2014070726 CrossRefPubMed

59.

Stock PG, Barin B, Murphy B et al (2010) Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 363(21):2004–2014. https://doi.org/10.1056/NEJMoa1001197 CrossRefPubMedPubMedCentral

60.

Alfano G, Mori G, Fontana F et al (2018) Clinical outcome of kidney transplantation in HIV-infected recipients: a retrospective study. Int J STD AIDS 29(13):1305–1315. https://doi.org/10.1177/0956462418779659 CrossRefPubMed

61.

Brehm MA, Markees TG, Daniels KA, Greiner DL, Rossini AA, Welsh RM (2003) Direct visualization of cross-reactive effector and memory allo-specific CD8 T cells generated in response to viral infections. J Immunol 170(8):4077–4086. https://doi.org/10.4049/jimmunol.170.8.4077 CrossRefPubMed

62.

Deeks SG (2011) HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 62:141–155. https://doi.org/10.1146/annurev-med-042909-093756 CrossRefPubMedPubMedCentral

63.

Langlois AJ, Weinhold KJ, Matthews TJ, Greenberg ML, Bolognesi DP (1992) Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses 8(9):1641–1652. https://doi.org/10.1089/aid.1992.8.1641 CrossRefPubMed

64.

Carter JT, Melcher ML, Carlson LL, Roland ME, Stock PG (2006) Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 6(4):753–760. https://doi.org/10.1111/j.1600-6143.2006.01238.x CrossRef

65.

van Leeuwen MT, Grulich AE, Webster AC et al (2009) Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 114(3):630–637. https://doi.org/10.1182/blood-2009-02-202507 CrossRefPubMed

66.

Müller TF, Grebe SO, Neumann MC et al (1997) Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 64(10):1432–1437. https://doi.org/10.1097/00007890-199711270-00010 CrossRefPubMed

67.

Kucirka LM, Durand CM, Bae S et al (2016) Induction immunosuppression and clinical outcomes in HIV-infected kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 16(8):2368–2376. https://doi.org/10.1111/ajt.13840 CrossRef

68.

Blumberg EA, Rogers CC (2013) Human immunodeficiency virus in solid organ transplantation. Am J Transplant 13(s4):169–178. https://doi.org/10.1111/ajt.12109 CrossRefPubMed

69.

Fumero E, García F, Gatell JM (2004) Immunosuppressive drugs as an adjuvant to HIV treatment. J Antimicrob Chemother 53(3):415–417. https://doi.org/10.1093/jac/dkh123 CrossRefPubMed

70.

Chapuis AG, Paolo Rizzardi G, D’Agostino C et al (2000) Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 6(7):762–768. https://doi.org/10.1038/77489 CrossRefPubMed

71.

Alfano G, Fontana F, Mori G et al (2019) Antiviral activity of sirolimus in an HIV-positive kidney transplant recipient. Int J STD AIDS 30(9):919–922. https://doi.org/10.1177/0956462419839520 CrossRefPubMed

72.

Perez CP, Patel N, Mardis CR, Meadows HB, Taber DJ, Pilch NA (2018) Belatacept in solid organ transplant: review of current literature across transplant types. Transplantation 102(9):1440–1452. https://doi.org/10.1097/TP.0000000000002291 CrossRefPubMed

73.

Ebcioglu Z, Liu C, Shapiro R et al (2016) Belatacept conversion in an HIV-positive kidney transplant recipient with prolonged delayed graft function. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 16(11):3278–3281. https://doi.org/10.1111/ajt.13923 CrossRef

74.

Marfo K, Greenstein S (2009) Antiretroviral and immunosuppressive drug-drug interactions in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplant Proc 41(9):3796–3799. https://doi.org/10.1016/j.transproceed.2009.06.186 CrossRefPubMed

75.

Mahalati K, Kahan BD (2001) Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40(8):573–585. https://doi.org/10.2165/00003088-200140080-00002 CrossRefPubMed

76.

White AJ (2001) Mitochondrial toxicity and HIV therapy. Sex Transm Infect 77(3):158–173. https://doi.org/10.1136/sti.77.3.158 CrossRefPubMedPubMedCentral

77.

Sawinski D, Shelton BA, Mehta S et al (2017) Impact of protease inhibitor-based anti-retroviral therapy on outcomes for HIV+ kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 17(12):3114–3122. https://doi.org/10.1111/ajt.14419 CrossRef

78.

Blumberg EA, Rogers CC (2013) AST infectious diseases community of practice. Human immunodeficiency virus in solid organ transplantation. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 13(Suppl 4):169–178. https://doi.org/10.1111/ajt.12109 CrossRef

79.

Segerer S, Mack M, Regele H, Kerjaschki D, Schlöndorff D (1999) Expression of the C-C chemokine receptor 5 in human kidney diseases1. Kidney Int 56(1):52–64. https://doi.org/10.1046/j.1523-1755.1999.00544.x CrossRefPubMed

80.

Frassetto LA, Tan-Tam C, Stock PG (2009) Renal transplantation in patients with HIV. Nat Rev Nephrol 5(10):582–589. https://doi.org/10.1038/nrneph.2009.140 CrossRefPubMedPubMedCentral

81.

Izzo I, Casari S, Bossini N et al (2018) Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy). Infection 46(1):77–82. https://doi.org/10.1007/s15010-017-1092-2 CrossRefPubMed

82.

Sawinski D, Kaur N, Ajeti A et al (2016) Successfultreatment of hepa titis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant 16(5):1588–1595. https://doi.org/10.1111/ajt.13620 CrossRefPubMed

83.

Benhamou Y, Bochet M, Di Martino V et al (1999) Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatol Baltim Md 30(4):1054–1058. https://doi.org/10.1002/hep.510300409 CrossRef

84.

Mocroft A, Neuhaus J, Peters L et al (2012) Hepatitis B and C Co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS ONE 7(7):e40245. https://doi.org/10.1371/journal.pone.0040245 CrossRefPubMedPubMedCentral

85.

Chang T-T, Lai C-L, Chien R-N et al (2004) Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 19(11):1276–1282. https://doi.org/10.1111/j.1440-1746.2004.03428.x CrossRefPubMed

86.

Chang T-T, Gish RG, de Man R et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354(10):1001–1010. https://doi.org/10.1056/NEJMoa051285 CrossRefPubMed

87.

Agarwal K, Brunetto M, Seto WK et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672–681. https://doi.org/10.1016/j.jhep.2017.11.039 CrossRefPubMed

88.

Izzedine H, Hulot JS, Launay-Vacher V et al (2004) Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int 66(3):1153–1158. https://doi.org/10.1111/j.1523-1755.2004.00866.x CrossRefPubMed

89.

Fabrizi F, Messa P (2018) Managing hepatitis C therapy failures and chronic kidney disease. Expert Rev Clin Pharmacol 11(11):1135–1142. https://doi.org/10.1080/17512433.2018.1534202 CrossRefPubMed

90.

Aggarwal A, Yoo ER, Perumpail RB et al (2017) Sofosbuvir use in the setting of end-stage renal disease: a single center experience. J Clin Transl Hepatol 5(1):23–26. https://doi.org/10.14218/JCTH.2016.00060 CrossRefPubMedPubMedCentral

91.

Li M, Chen J, Fang Z, Li Y, Lin Q (2019) Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virol J 16(1):34. https://doi.org/10.1186/s12985-019-1140-x CrossRefPubMedPubMedCentral

92.

Gane E, Lawitz E, Pugatch D et al (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377(15):1448–1455. https://doi.org/10.1056/NEJMoa1704053 CrossRefPubMed

93.

Rockstroh JK, Lacombe K, Viani RM et al (2018) Efficacy and safety of glecaprevir/pibrentasvir in patients coinfected with hepatitis C virus and human immunodeficiency virus type 1: the EXPEDITION-2 study. Clin Infect Dis Off Publ Infect Dis Soc Am 67(7):1010–1017. https://doi.org/10.1093/cid/ciy220 CrossRef

94.

Roth D, Nelson DR, Bruchfeld A et al (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. The Lancet 386(10003):1537–1545. https://doi.org/10.1016/S0140-6736(15)00349-9 CrossRef

95.

Recommendations for Testing, Managing, and Treating Hepatitis C | HCV Guidance. https://www.hcvguidelines.org/. Accessed 7 August 2019

96.

Sherer R, Stieglitz K, Narra J et al (2002) HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care 14(Suppl 1):S31–44. https://doi.org/10.1080/09540120220149975 CrossRefPubMed

Title: Therapeutic management of HIV-infected patients with chronic kidney disease
Authors: Gaetano Alfano
Giovanni Guaraldi
Francesco Fontana
Antonio Bellasi
Gianni Cappelli
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Kidney Transplantation
Kidney Transplantation
Kidney Transplantation
Lamivudine
Human Immunodeficiency Virus
Kidney Transplantation
Kidney Transplantation
Chronic Kidney Disease
Kidney Transplantation
Lamivudine
Published in: Journal of Nephrology / Issue 4/2020
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-020-00701-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Uric acid in CKD: has the jury come to the verdict?

Propionate supplementation promotes the expansion of peripheral regulatory T-Cells in patients with end-stage renal disease

Centromere protein I (CENPI) is a candidate gene for X-linked steroid sensitive nephrotic syndrome

Recurrent antibody-mediated rejection in renal allograft: physician’s dilemma

Green nephrology and eco-dialysis: a position statement by the Italian Society of Nephrology

Smile! (Life will be better)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials